JWH-298
JWH-298 is a synthetic cannabinoid that acts as a potent agonist at both the CB1 and CB2 cannabinoid receptors. It is part of the naphthoylindole family of synthetic cannabinoids, which were originally developed for research purposes to study the endocannabinoid system.
Chemical Structure and Properties[edit | edit source]
JWH-298 is chemically classified as a naphthoylindole, with the systematic IUPAC name (1-pentyl-1H-indol-3-yl)-1-naphthalenylmethanone. The compound has a molecular formula of C24H23NO and a molar mass of 341.45 g/mol. Its structure consists of a naphthalene group attached to a methanone bridge, which is further connected to an indole group with a pentyl chain at the nitrogen atom.
Pharmacology[edit | edit source]
JWH-298 is known to bind to the CB1 and CB2 receptors, which are part of the endocannabinoid system. These receptors are involved in a variety of physiological processes including pain sensation, mood regulation, and appetite. JWH-298 has been shown to have a higher affinity for the CB2 receptor, which is primarily found in the immune system, compared to the CB1 receptor, which is predominantly located in the central nervous system.
Legal Status[edit | edit source]
The legal status of JWH-298 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. It is often included in legislation targeting synthetic cannabinoids and "designer drugs."
Research and Applications[edit | edit source]
JWH-298, like other synthetic cannabinoids, has been used in scientific research to better understand the endocannabinoid system and the effects of cannabinoids on the body. However, due to its psychoactive properties and potential for abuse, its use is restricted to controlled laboratory settings.
Health Effects and Risks[edit | edit source]
The use of JWH-298 outside of a research context is associated with significant health risks. Synthetic cannabinoids can cause a range of adverse effects, including anxiety, paranoia, tachycardia, and in severe cases, psychosis. The long-term health effects of JWH-298 are not well understood, but it is considered to be potentially harmful.
Also see[edit | edit source]
- Synthetic cannabinoids
- Endocannabinoid system
- CB1 receptor
- CB2 receptor
- JWH-018
- Cannabinoid receptor agonists
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD